FindTrial
Sign In

Impact of combination of rivaroxaban with amiodarone on bleeding in atrial fibrillation patients with renal dysfunction

Impact of combination of rivaroxaban with amiodarone on bleeding in atrial fibrillation patients with renal dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062662
Enrollment
Unknown
Registered
2022-08-15
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Severe renal dysfunction:None
Moderate renal dysfunction:None
Mild renal dysfunction:None
Normal renal dysfunction:None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Treatment with rivaroxaban; 3. Treatment with amiodarone.

Exclusion criteria

Exclusion criteria: 1. Receiving other oral anticoagulants, including warfarin, dabigatran and apixaban; 2. Severe infectious diseases, maliglant tumor and malnutrition.

Design outcomes

Primary

MeasureTime frame
Bleeding;—

Countries

China

Contacts

Public ContactZi Wang

Zhongshan Hospital, Fudan University

wang.zi@zs-hospital.sh.cn+86 18818263550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026